Johnson & Johnson CEO Discusses Q4 2013 Results - Earnings Call Transcript
Johnson & Johnson ( JNJ ) Q4 2013 Results Earnings Call January 21, 2014 8:30 AM ET
Good morning, and welcome. I’m Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the fourth quarter and full year of 2013.
Joining me on the podium today are Alex Gorsky, Chairman of the Board and Chief Executive Officer, and Dominic Caruso, Vice President, Finance and Chief Financial Officer. A few logistics before we get into the details.
This review is being made available to a broader audience via a webcast accessible through the Investor Relations section of the Johnson & Johnson website. I’ll begin by briefly reviewing highlights of the fourth quarter and full year of 2013 for the corporation and highlights for our three business segments.
Following my remarks, Alex will comment on the 2013 results and provide a strategic outlook for the company. Dominic will then provide some additional commentary on financial results and guidance for 2014. We will then open the meeting to your questions. We expect the meeting to conclude at approximately 10:15.
Tornier Reports Second Quarter 2014 Results
- Baxano Surgical's products include AxiaLIF, VEO, iO-Flex, and the AVANCE MIS Pedicle Screw System. The AxiaLIF system provides a minimally invasive alternative to open spinal fusion procedures, while the VEO Lateral Access and Interbody Fusion
- This progress, combined with ongoing adoption of our market leading Aequalis Ascend Flex shoulder system and solid international performance, resulted in strong financial results in the second quarter, including double-digit upper extremities growth.”.
- Second quarter 2013 revenue included $0.8 million contributed by the iO-Flex® and iO-Tome® products acquired in connection with our acquisition of Baxano, Inc. on May 31, 2013, the operations of which have been included in our consolidated financial